Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells
- 1 July 1998
- journal article
- Published by Elsevier in Immunopharmacology
- Vol. 40 (1) , 1-9
- https://doi.org/10.1016/s0162-3109(98)00012-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Evidence for a Pathway Independent from 2′‐Deoxyguanosine and Reversible by IL‐2 by which Purine Nucleoside Phosphorylase Inhibitors Block T‐Cell ProliferationScandinavian Journal of Immunology, 1994
- PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR)Inflammation Research, 1993
- Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(Arylmethyl) derivatives of 9-deazaguanineJournal of Medicinal Chemistry, 1993
- T-Lymphocyte-Antigen Interactions in Transplant RejectionNew England Journal of Medicine, 1990
- The T-Cell Receptor Repertoire and Autoimmune DiseasesAnnual Review of Immunology, 1989
- Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stagesInternational Journal of Immunopharmacology, 1988
- Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitorInflammation Research, 1987
- Phytohemagglutinin binds to the 20‐kDa molecule of the T3 complexEuropean Journal of Immunology, 1985
- T‐Cell Growth FactorImmunological Reviews, 1980
- Allosteric regulation of calf thymus ribonucleoside diphosphate reductaseBiochemistry, 1979